
# Q&A Webinar

### June 25, 2020 @ 3 PM EDT

Please submit your questions in the "Q&A" box (specific questions about scientific fit will not be addressed) NIH DIRECTOR'S NEW INNOVATOR AWARD





National Institutes of Health Office of Strategic Coordination - The Common Fund

### Panelists

### Ravi Basavappa, Ph.D.

Program Leader Office of the Director

### Becky Miller, Ph.D.

Program Officer Office of the Director

### Eugene Carstea, Ph.D.

Branch Chief Center for Scientific Review

### Ellie Murcia, M.Ed.

Program Specialist Office of the Director

### The Common Fund (in the NIH Office of the Director) Current Programs:



#### Data/Tools/Methods

- Big Data to Knowledge (BD2K)
- Gabriella Miller Kids First
- Genotype-Tissue Expression (GTEx)
- Glycoscience
- Human BioMolecular Atlas Program (HuBMAP)
- Illuminating the Druggable Genome (IDG)
- Knockout Mouse Phenotyping (KOMP)
- Library of Integrated Network-Based Cellular Signatures (LINCS)

- Metabolomics
- Regenerative Medicine Program (RMP)
- Science of Behavior Change (SOBS)
- Somatic Cell Genome Editing (SCGE)
- Stimulating Peripheral Activity to Relieve Conditions (SPARC)
- Transformative High Resolution Cryo-Electron Microscopy (CryoEM)



The Common Fund

### **New Types of Clinical Partnerships**

- Acute to Chronic Pain Signatures (A2CPS)
- Global Health
- HCS Research Collaboratory
- Undiagnosed Diseases Network (UDN)

#### **Transformative Workforce Support**

- Enhancing the Diversity of the NIH-Funded Workforce (DPC/BUILD)
- High-Risk, High-Reward Research Program
  - Pioneer Award
  - New Innovator Award
  - Transformative Research Award
  - Early Independence Award
- Strengthening the Biomedical Research Workforce (BEST)

#### **New Paradigms**

- 4D Nucleome (4DN)
- Extracellular RNA Communication (exRNA)
- Molecular Transducers of Physical Activity Consortium (MoTrPAC)

### The Common Fund (in the NIH Office of the Director) **Current Programs:**



#### Data/Tools/Methods

- Big Data to Knowledge (BD2K)
- Gabriella Miller Kids First
- Genotype-Tissue Expression (GTEx)
- Glycoscience
- Human BioMolecular Atlas Program (HuBMAP)
- Illuminating the Druggable Genome (IDG)
- Knockout Mouse Phenotyping (KOMP)
- Library of Integrated Network-Based Cellular Signatures (LINCS)

- Metabolomics
- Regenerative Medicine Program (RMP)
- Science of Behavior Change (SOBS)
- Somatic Cell Genome Editing (SCGE)
- Stimulating Peripheral Activity to **Relieve Conditions (SPARC)**
- Transformative High Resolution Cryo-Electron Microscopy (CryoEM)

reagents, protocols, ....

### **New Types of Clinical Partnerships**

- Acute to Chronic Pain Signatures (A2CPS)
- Global Health

Tra

- HCS Research Collaboratory
- Undiagnosed Diseases Network (UDN)

## NIH

The Common Fund

### ative Workforce Support

iversity of the NIH-Funded Workforce (DPC/BUILD) Reward Research Program

---- Award

- New Innovator Award
- Transformative Research Award
- FOAs, access to high-end instruments, databases, Early Independence Award
  - Strengthening the Biomedical Research Workforce (BEST)

#### **New Paradigms**

- 4D Nucleome (4DN)
- CF programs may be useful for your research: Extracellular RNA Communication (exRNA)
- Molecular Transducers of Physical Activity C

### The Common Fund (in the NIH Office of the Director) Current Programs:



#### Data/Tools/Methods

- Big Data to Knowledge (BD2K)
- Gabriella Miller Kids First
- Genotype-Tissue Expression (GTEx)
- Glycoscience
- Human BioMolecular Atlas Program (HuBMAP)
- Illuminating the Druggable Genome (IDG)
- Knockout Mouse Phenotyping (KOMP)
- Library of Integrated Network-Based Cellular Signatures (LINCS)

- Metabolomics
- Regenerative Medicine Program (RMP)
- Science of Behavior Change (SOBS)
- Somatic Cell Genome Editing (SCGE)
- Stimulating Peripheral Activity to Relieve Conditions (SPARC)
- Transformative High Resolution Cryo-Electron Microscopy (CryoEM)



The Common Fund

### **New Types of Clinical Partnerships**

- Acute to Chronic Pain Signatures (A2CPS)
- Global Health
- HCS Research Collaboratory
- Undiagnosed Diseases Network (UDN)

#### **Transformative Workforce Support**

- Enhancing the Diversity of the NIH-Funded Workforce (DPC/BUILD)
- High-Risk, High-Reward Research Program
  - Pioneer Award
  - New Innovator Award
  - Transformative Research Award
  - Early Independence Award
- Strengthening the Biomedical Research Workforce (BEST)

#### **New Paradigms**

- 4D Nucleome (4DN)
- Extracellular RNA Communication (exRNA)
- Molecular Transducers of Physical Activity Consortium (MoTrPAC)



### Annual funding opportunities



### High-risk, high-impact ideas



# No preliminary data or detailed experimental plan required



### Any topic relevant to NIH mission

### High-Risk, High-Reward Research Program





Any topic relevant to NIH mission, including: behavioral, social, biomedical, applied, and formal sciences, and basic, translational, or clinical research

### High-Risk, High-Reward Research Program





Encourages applications from investigators with diverse backgrounds and from the full spectrum of eligible institutions

### High-Risk, High-Reward Research Program



The Common Fund

Chair

James M. Anderson, MD, PhD NCATS OD Judith

Program Leader

Ravi Basavappa, PhD OSC/DPCPSI/OD

#### <u>Members</u>

Kristin Abraham, PhD NIDDK

Vernon Anderson, PhD NIGMS

Hugh Auchincloss, MD NIAID

David Balshaw, PhD NIEHS

Abraham P. Bautista, PhD NIAAA

Eugene Carstea, PhD CSR

Robert H Carter, MD NIAMS

Jennifer Collins, MR NIEHS Christine Colvis, PhD PhD NCATS

> Judith A. Cooper, PhD NIDCD Milton Corn, MD, FACP,

> FACMI NLM

**Cindy D. Davis, PhD** Office of Dietary Supplements/DPCPSI/OD

Emmeline Edwards, PhD NCCIH

Zeynep Erim, PhD NIBIB

**Rene Etcheberrigaray, MD** NIA

Valerie Florance, PhD NLM

Gabriel Hidalgo NIDCR

Christine Hunter, PhD, ABPP OBSSR/DPCPSI/OD

Raymond Jacobson, PhD CSR Flora Katz, PhD FIC

Karen Kellton OSC/DPCPSI/OD

Anthony Kirilusha, PhD NIAMS

Susan Koester, PhD NIMH

Rajiv Kumar, PhD CSR

James Li, PhD CSR

Roger Little, PhD NIDA

James Mack, PhD CSR

Judy A. Mietz, PhD NCI

Becky Miller, PhD OSC/DPCPSI/OD

Brett Miller, PhD NICHD

Daniel Miller, PhD NINDS

Michael Morse OSC/DPCPSI/OD Ellie Murcia, MEd OSC/DPCPSI/OD Srikanth Ranganathan, PhD CSR Diana (Dede) Rutberg, MBA NIDCR Suzanne Ryan, PhD CSR John Satterlee, PhD NIDA **Carol Shreffler, PhD** NIEHS Lillian Shum, PhD NIDCR Darren Sledjeski, PhD NIDCR Heidi J. Sofia, PhD NHGRI

Michael A. Steinmetz, PhD NEI Nathaniel Stinson, Jr., PhD, MD NIMHD Edmund Talley, PhD NINDS Stephanie Johnson Webb, PhD NHLBI Tasmeen Weik, DrPH, MPH CSR

Elizabeth L. Wilder, PhD OSC/DPCPSI/OD





Supports unusually creative early career investigators proposing innovative, high-impact research

- Started in 2007
- Early Stage Investigator (no substantial NIH grant and within 10 years of doctoral degree or clinical training)
- Commit 25% research effort
- Awards of \$1.5 million disbursed in first year of 5 year project period
- Uses DP2 activity code

### **New Innovator Award - application**



#### Follow instructions in SF424 application guide unless specific guidance is provided in the FOA

Specific Aims Page	Do not use
Research Strategy Essay	10 pages (primary component of the application; see later slide for more information)
Biosketch	Only PI's biosketch allowed
Bibliography & References Cited	Do not use; include essential in references in Essay and within 10 page limit
Budget	No detailed budget allowed (indicate only \$1.5M)
Equipment	Do not use
Letters of support	Do not use
Resource Sharing Plan	Do not use; will be requested as Just-in-Time information
Other components/forms	Use when appropriate, such as Authentication of Key Biol./Chem. Resources; Vertebrate Animals; Human Subjects; Biohazards

### New Innovator Award - application



#### Follow instructions in SF424 application guide unless specific guidance is provided in the FOA

Specific Aims Page	Do not use
Research Strategy Essay	10 pages (primary component of the application; see later slide for more information)
Biosketch	Only PI's biosketch allowed
Bibliography & References Cited	Do not use; include essential in references in Essay and within 10 page-limit
Budget	No detailed budget allowed (indicate only \$1.5M)
Equipment	Do not use
Letters of support	Do not use
Resource Sharing Plan	Do not use; will be requested as Just-in-Time information
Other components/forms	Use when appropriate, such as Authentication of Key Biol./Chem. Resources; Vertebrate Animals; Human Subjects; Biohazards

### New Innovator Award – Research Strategy Essay



In 10 pages, use the following headings or subsections:

- **Project science areas** 1 digit code and abbreviation for primary and secondary areas
- **Project Description** Describe scientific importance of topic; overall approach to be taken; preliminary data not required, but accepted; state that to comply with the FOA, a detailed experimental plan and extensive are not being provided; however, provide sufficient evidence that proposal has been deeply considered and will be pursued in a robust and rigorous manner
- Innovativeness Provide argument of why proposal is exceptionally innovative
- Investigator qualifications Support your claim of innovativeness in prior research
- Suitability for the New Innovator Award program Describe why proposal is "HRHR"
- **Statement of research effort commitment** State will commit at least 25% research effort toward project
- **Bibliography/citations** Include critical citations; may be in an abbreviated form as long as identifier is unique

#### **Points to consider:**

- Given review process used, be sure that what you write can be easily appreciated by people well outside the field for exceptional innovation and potential for unusually broad impact
- May be helpful to begin with a description of the landscape of the field and current state-of-the-art or boundaries; provide proper context for proposal and why it is so innovative and potentially impactful
- Ease the reader into the jargon of the field
- Though no data or detailed experimental plan are required, convince the reviewer that you have thought deeply about the project identify risky aspects, how they will be mitigated, alternate approaches
- Also, convince the reviewer that the research will be performed in a robust and rigorous manner validate new approaches, provide estimates of numbers of human or animal subjects (if used) and why, include that sex will be considered as a biological variable (if appropriate)

The Common Fund

U.S. Department of Health & Human Services



### NIH Director's New Innovator Award (DP2)

Gene Carstea, PhD Scientific Review Officer, New Innovator Award Review


Chief, Cardiovascular and Respiratory Sciences (CVRS) IRG CSR, NIH

2020-21 Webinar June 25, 2020





### **New Innovator Award Review Process**








### **Peer-Review Process – Pre-Stage 1**

- All applications are assigned to one panel
  located within the *Cardiovascular and Respiratory Sciences* (CVRS) IRG
- > Administrative Review: A check for completeness and ESI eligibility
- > Applications are grouped based on areas of science, as identified by applicant
- Potential Conflicts of Interest will be considered for each application
  o e.g., Institutional, Collaborative, etc.
- > Mail Reviewers will be recruited to cover all representative areas of science





### **Peer-Review Process: Stage 1 (Mail Reviews)**



- 2. "Novelty / Innovativeness of Approach"
- 3. "Creative Potential of ESI"

#### **Overall Impact Paragraph**





### **Selection of Finalists for Stage 2**

- ✓ Selection based on Rank Score order by Mail reviewers
  - Overall Impact Scores
- ✓ Unbiased selection of applications by Editorial reviewers
  - Combination of Scores and Impact statements

In total: Approx. 20% of all submitted applications will advance to Stage 2







### **Stage 2: Editorial Review**

- "Editorial board" consisting of ~25 panelists
  - $\circ$   $\,$  senior members of the scientific community
  - experts with broad scientific understanding
- Each finalist application is assigned to 3 Editor/Reviewers
  - $\circ$   $\,$  all finalist applications will be discussed
- Scoring is focused on Impact & Innovation
- Each assigned Editor/Reviewer provides an impact statement and impact score
- Release of final scores and Summary Statements (for all)
  - Discussed statements: will receive 2<sup>nd</sup> stage impact statements with resume and summary of discussion
  - Non-discussed statements: will receive 1<sup>st</sup> stage critiques





### **Questions about the Review process**

### Contact:

### Gene Carstea SRO, New Innovator Award Chief, CVRS IRG 301-827-3384; <u>carsteae@csr.nih.gov</u>



# Q&A Webinar


### June 25, 2020 @ 3 PM EDT

Please submit your questions in the "Q&A" box (scientific inquiries will not be discussed)

Eligibility



National Institutes of Health Office of Strategic Coordination - The Common Fund NIH DIRECTOR'S NEW INNOVATOR AWARD




# Q&A Webinar

### June 25, 2020 @ 3 PM EDT

Please submit your questions in the "Q&A" box (scientific inquiries will not be discussed)

Application & Submission

#### NIH DIRECTOR'S NEW INNOVATOR AWARD







Office of Strategic Coordination - The Common Fund

# Q&A Webinar


### June 25, 2020 @ 3 PM EDT

Please submit your questions in the "Q&A" box (scientific inquiries will not be discussed)

Budget



National Institutes of Health Office of Strategic Coordination - The Common Fund NIH DIRECTOR'S NEW INNOVATOR AWARD




# Q&A Webinar

### June 25, 2020 @ 3 PM EDT

Please submit your questions in the "Q&A" box (scientific inquiries will not be discussed)

Review









# Q&A Webinar

### June 25, 2020 @ 3 PM EDT

Thank you for attending.

A recording of this webinar will be made available on <u>https://commonfund.nih.gov/newinnovator</u>.

If you have additional questions, email us at <u>newinnovator@mail.nih.gov</u>.



NIH DIRECTOR'S NEW INNOVATOR AWARD

